Moleculin Biotech, Inc. announced that Chairman and CEO Walter Klemp will participate in a live video webcast on December 2nd at 4:00 PM ET. The event will include a corporate overview and business outlook, with a Q&A session for participants. The webcast will be available on the Company’s website, with a replay accessible for 90 days. Moleculin is a Phase 3 clinical stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses. Their lead program, Annamycin, is in development for relapsed/refractory AML and STS lung metastases. They are also working on WP1066 and WP1122 for various cancers and viruses.

Read more at GlobeNewswire: Moleculin to Participate in the Virtual Investor Closing